← All trials
NCT05350124
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2022
- Primary completion
- Dec 31, 2023
- Completion date
- Dec 31, 2023
- First posted
- Apr 27, 2022
- Last posted
- Aug 24, 2022
- Enrollment
- 160
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- King Abdul-Aziz UniversityLead sponsor
- King Abdul-Aziz UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.